Market Access Communication
Client situation
The German branch of a research-based pharmaceutical company was preparing for the early benefit assessment with an innovative gastroenterological drug. The value proposition for the drug in the global value dossier did not seem to fit the German healthcare context in terms of patient benefit.
Our solution
co.patient contacted several German patient organisations and organised a Patient Advisory Board meeting. At this meeting, our client's employees had discussions with patients.
Client benefits
co.patient mediated the exchange with patients in order to give our client a better understanding of the benefits of his drug in the specific context of German patients. Also, important multipliers were made aware of our client's new drug and its benefits. This was of great advantage in the further course of the benefit assessment procedure.